Inclusion criteria, exclusion criteria and study summary
• Men and women with idiopathic PD (Hoehn & Yahr scale 1-2) • Age between 40 and 85 years old • 0-5 years since diagnosis • Normal or corrected vision • Ability to follow instructions • Willing and able to sign an informed consent form • No anticipated changes in PD medications from baseline throughout the study duration based on clinical status during screening. • If treated, stable on current treatment for at least 3 months.
• Inability to sit for 20 minutes on a chair in a calm manner • Personal or 1st degree relative history of epilepsy • Additional neurological diseases • Drug or alcohol abuse (except for using medical cannabis during 24 hours prior NL examination date) • Pregnancy or a potential pregnancy (self-declaration).
This is an observational prospective longitudinal multicenter study, in a population of up to 300 patients with idiopathic PD. All patients will be assessed using MDS-UPDRS and MoCA test over a period of 12 months (5 assessments, at 0, 3, 6, 9, 12 months). During this time period, every subject who consents will undergo a NeuraLight session including oculometric measurements and eye-tracking recordings using a novel software-based platform and an eye-tracking system. No randomisation is applicable.
